The demand grants were approved by PTC’s Compensation Committee on September 8, 2024, and are made as incentives for each employee’s employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have a closing price of $31.54 per share PTC (NASDAQ:) common stock on September 6, 2024, the immediately preceding trading day. Each of the stock options has a term of 10 years and vests over four years, 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and 6.25% of the original number of shares vesting at the end. for every subsequent three-month period thereafter until fully vested, subject to the employee’s continued service with the company during the respective vesting dates. Each of the RSUs will vest over four years, 25% of the original number of shares until fully vested on each anniversary of the applicable employee’s new hire date, subject to the employee’s continuous service with the company during the applicable vesting dates.
ABOUT PTC THERAPEUTICS, INC.
PTC is a science-based, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that benefit patients with rare diseases. PTC’s ability to innovate to identify new therapies and commercialize products globally is key to investing in a robust and diversified pipeline of transformational medicines. PTC’s mission is to provide access to best-in-class treatments for patients with few or no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring treatments to patients. PTC believes this maximizes value for all stakeholders. To learn more about PTC, visit www.ptcbio.com and follow us on Instagram, Facebook (NASDAQ:), Twitter and LinkedIn.
For more information, contact:
jclemente@ptcbio.com
